OGN (Organon) Valuation Rank


OGN Organon & Co OGN
71 GF Score
Price $13.50
GF Value $14.55
Valuation Fairly Valued
! 9 Warning Signs
View Full Analysis

What is Organon Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Organon Valuation Rank Related Terms

OGN
71GF Score
Organon & Co OGN
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Organon (OGN) Overvalued in 2026?

Based on GuruFocus' analysis, Organon stock appears to be undervalued. The current stock price of $13.50 is trading 7.2% below its estimated GF Value™ of $14.55. GuruFocus considers Organon to be Fairly Valued.

Key valuation signals for OGN:

  • Valuation Rank:
  • GF Value™: $14.55 vs. price of $13.50 (7.2% below fair value)
  • GF Score™: 71/100 with 9 warning signs

No single metric tells the full story. See the OGN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Organon Business Description

Address 30 Hudson Street, Floor 33, Jersey City, NJ, USA, 07302
Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.
71GF Score

Get the complete analysis for OGN

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$13.50
Price
$14.55
GF Value